BR112021002917A2 - composições compreendendo cepas bacterianas - Google Patents

Info

Publication number

BR112021002917A2

BR112021002917A2 BR112021002917-6A BR112021002917A BR112021002917A2 BR 112021002917 A2 BR112021002917 A2 BR 112021002917A2 BR 112021002917 A BR112021002917 A BR 112021002917A BR 112021002917 A2 BR112021002917 A2 BR 112021002917A2

Authority

BR

Brazil

Prior art keywords

composition

compositions

strain

bacterial

cells

Prior art date

2018-08-17

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000203 mixture Substances 0.000 title claims abstract description 397
• 230000001580 bacterial effect Effects 0.000 title claims abstract description 203
• 210000000987 immune system Anatomy 0.000 claims abstract description 43
• 230000004936 stimulating effect Effects 0.000 claims abstract description 40
• 108090000623 proteins and genes Proteins 0.000 claims description 173
• 238000011282 treatment Methods 0.000 claims description 148
• 241000186012 Bifidobacterium breve Species 0.000 claims description 128
• 229920002444 Exopolysaccharide Polymers 0.000 claims description 85
• 230000000694 effects Effects 0.000 claims description 82
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 78
• 230000014509 gene expression Effects 0.000 claims description 71
• 239000000427 antigen Substances 0.000 claims description 69
• 108091007433 antigens Proteins 0.000 claims description 69
• 102000036639 antigens Human genes 0.000 claims description 69
• 201000010099 disease Diseases 0.000 claims description 69
• 230000001965 increasing effect Effects 0.000 claims description 67
• 208000035143 Bacterial infection Diseases 0.000 claims description 57
• 208000022362 bacterial infectious disease Diseases 0.000 claims description 57
• 238000000034 method Methods 0.000 claims description 45
• 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 39
• 229940124931 vaccine adjuvant Drugs 0.000 claims description 35
• 239000012646 vaccine adjuvant Substances 0.000 claims description 35
• 230000002265 prevention Effects 0.000 claims description 33
• 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims description 32
• 102100024333 Toll-like receptor 2 Human genes 0.000 claims description 32
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 28
• 108090000978 Interleukin-4 Proteins 0.000 claims description 25
• 230000003308 immunostimulating effect Effects 0.000 claims description 22
• SRBFZHDQGSBBOR-MBMOQRBOSA-N alpha-D-arabinopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-MBMOQRBOSA-N 0.000 claims description 20
• 229960005486 vaccine Drugs 0.000 claims description 19
• 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims description 17
• 230000002829 reductive effect Effects 0.000 claims description 17
• 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims description 16
• 108090000637 alpha-Amylases Proteins 0.000 claims description 16
• 238000002659 cell therapy Methods 0.000 claims description 16
• MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 15
• MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 15
• 108010047754 beta-Glucosidase Proteins 0.000 claims description 15
• MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 15
• 102000006995 beta-Glucosidase Human genes 0.000 claims description 14
• 108010030291 alpha-Galactosidase Proteins 0.000 claims description 13
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
• 102000005840 alpha-Galactosidase Human genes 0.000 claims description 12
• 108020004465 16S ribosomal RNA Proteins 0.000 claims description 11
• 230000000638 stimulation Effects 0.000 claims description 11
• 208000029462 Immunodeficiency disease Diseases 0.000 claims description 9
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 8
• 206010054979 Secondary immunodeficiency Diseases 0.000 claims description 7
• 108010028144 alpha-Glucosidases Proteins 0.000 claims description 6
• 208000028529 primary immunodeficiency disease Diseases 0.000 claims description 5
• 230000003190 augmentative effect Effects 0.000 claims description 4
• 108010005774 beta-Galactosidase Proteins 0.000 claims description 4
• 208000027096 gram-negative bacterial infections Diseases 0.000 claims description 3
• 208000033065 inborn errors of immunity Diseases 0.000 claims description 3
• 208000032839 leukemia Diseases 0.000 claims description 3
• 208000030507 AIDS Diseases 0.000 claims description 2
• 206010019799 Hepatitis viral Diseases 0.000 claims description 2
• 208000024781 Immune Complex disease Diseases 0.000 claims description 2
• 208000034578 Multiple myelomas Diseases 0.000 claims description 2
• 201000001862 viral hepatitis Diseases 0.000 claims description 2
• 206010068306 Gastrointestinal bacterial infection Diseases 0.000 claims 1
• 102100024295 Maltase-glucoamylase Human genes 0.000 claims 1
• 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
• 102000005936 beta-Galactosidase Human genes 0.000 claims 1
• 201000007294 immune system cancer Diseases 0.000 claims 1
• 210000004027 cell Anatomy 0.000 description 165
• 241000894006 Bacteria Species 0.000 description 147
• 102000004169 proteins and genes Human genes 0.000 description 130
• 235000018102 proteins Nutrition 0.000 description 128
• 238000012360 testing method Methods 0.000 description 92
• 239000002609 medium Substances 0.000 description 60
• 238000000855 fermentation Methods 0.000 description 48
• 230000004151 fermentation Effects 0.000 description 48
• 206010028980 Neoplasm Diseases 0.000 description 42
• 238000004458 analytical method Methods 0.000 description 40
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 38
• 102000004127 Cytokines Human genes 0.000 description 36
• 108090000695 Cytokines Proteins 0.000 description 36
• 241000894007 species Species 0.000 description 35
• 239000000725 suspension Substances 0.000 description 32
• 239000008194 pharmaceutical composition Substances 0.000 description 31
• 238000009634 analytical profile index Methods 0.000 description 30
• 239000008186 active pharmaceutical agent Substances 0.000 description 29
• 230000004044 response Effects 0.000 description 29
• 210000003719 b-lymphocyte Anatomy 0.000 description 26
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 26
• 239000006228 supernatant Substances 0.000 description 26
• 241000699670 Mus sp. Species 0.000 description 25
• 230000000845 anti-microbial effect Effects 0.000 description 25
• 230000028993 immune response Effects 0.000 description 25
• 102000004388 Interleukin-4 Human genes 0.000 description 24
• 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 23
• 241001465754 Metazoa Species 0.000 description 23
• 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 23
• 241000588724 Escherichia coli Species 0.000 description 22
• 108090000765 processed proteins & peptides Proteins 0.000 description 22
• 230000003247 decreasing effect Effects 0.000 description 21
• 230000001225 therapeutic effect Effects 0.000 description 21
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 20
• 238000003556 assay Methods 0.000 description 20
• 208000015181 infectious disease Diseases 0.000 description 20
• 210000000936 intestine Anatomy 0.000 description 20
• 150000001720 carbohydrates Chemical class 0.000 description 19
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 18
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 18
• 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 18
• 210000002490 intestinal epithelial cell Anatomy 0.000 description 18
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 17
• 235000014633 carbohydrates Nutrition 0.000 description 17
• 238000000338 in vitro Methods 0.000 description 17
• 239000003981 vehicle Substances 0.000 description 17
• 239000012228 culture supernatant Substances 0.000 description 16
• 230000006806 disease prevention Effects 0.000 description 16
• 102000004196 processed proteins & peptides Human genes 0.000 description 16
• 238000003906 pulsed field gel electrophoresis Methods 0.000 description 16
• 241000186000 Bifidobacterium Species 0.000 description 15
• 239000002775 capsule Substances 0.000 description 15
• 238000002474 experimental method Methods 0.000 description 15
• 238000004519 manufacturing process Methods 0.000 description 15
• 230000001105 regulatory effect Effects 0.000 description 15
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
• 238000009472 formulation Methods 0.000 description 14
• 210000001035 gastrointestinal tract Anatomy 0.000 description 14
• 230000003389 potentiating effect Effects 0.000 description 14
• 230000000770 proinflammatory effect Effects 0.000 description 14
• 210000003289 regulatory T cell Anatomy 0.000 description 13
• 210000001744 T-lymphocyte Anatomy 0.000 description 12
• 102100028601 Transaldolase Human genes 0.000 description 12
• 108020004530 Transaldolase Proteins 0.000 description 12
• 239000003085 diluting agent Substances 0.000 description 12
• 239000013612 plasmid Substances 0.000 description 12
• 230000028327 secretion Effects 0.000 description 12
• 238000002560 therapeutic procedure Methods 0.000 description 12
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 11
• 108020004414 DNA Proteins 0.000 description 11
• 241000699666 Mus <mouse, genus> Species 0.000 description 11
• 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 11
• 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 11
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 11
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 11
• 201000011510 cancer Diseases 0.000 description 11
• 230000008859 change Effects 0.000 description 11
• 238000006243 chemical reaction Methods 0.000 description 11
• 235000013305 food Nutrition 0.000 description 11
• 239000001963 growth medium Substances 0.000 description 11
• 210000005260 human cell Anatomy 0.000 description 11
• 239000013642 negative control Substances 0.000 description 11
• 239000013641 positive control Substances 0.000 description 11
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
• 230000005526 G1 to G0 transition Effects 0.000 description 10
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 10
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 10
• 108090000631 Trypsin Proteins 0.000 description 10
• 102000004142 Trypsin Human genes 0.000 description 10
• 239000000872 buffer Substances 0.000 description 10
• 239000012091 fetal bovine serum Substances 0.000 description 10
• 238000000684 flow cytometry Methods 0.000 description 10
• 230000012010 growth Effects 0.000 description 10
• 230000036961 partial effect Effects 0.000 description 10
• 230000001737 promoting effect Effects 0.000 description 10
• 210000000130 stem cell Anatomy 0.000 description 10
• 239000012588 trypsin Substances 0.000 description 10
• 235000014469 Bacillus subtilis Nutrition 0.000 description 9
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
• 102000018697 Membrane Proteins Human genes 0.000 description 9
• 108010052285 Membrane Proteins Proteins 0.000 description 9
• 239000012980 RPMI-1640 medium Substances 0.000 description 9
• 239000003153 chemical reaction reagent Substances 0.000 description 9
• 239000008103 glucose Substances 0.000 description 9
• 230000001404 mediated effect Effects 0.000 description 9
• 238000001543 one-way ANOVA Methods 0.000 description 9
• -1 pGTF Proteins 0.000 description 9
• 239000000047 product Substances 0.000 description 9
• 239000000523 sample Substances 0.000 description 9
• 230000035899 viability Effects 0.000 description 9
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
• 229920001817 Agar Polymers 0.000 description 8
• 101710180684 Beta-hexosaminidase Proteins 0.000 description 8
• 101710124976 Beta-hexosaminidase A Proteins 0.000 description 8
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 8
• 102000014914 Carrier Proteins Human genes 0.000 description 8
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
• 102100030122 Protein O-GlcNAcase Human genes 0.000 description 8
• 101710081801 Protein O-GlcNAcase Proteins 0.000 description 8
• 101710199095 Putative beta-hexosaminidase Proteins 0.000 description 8
• 108050000761 Serpin Proteins 0.000 description 8
• 102000008847 Serpin Human genes 0.000 description 8
• 230000004913 activation Effects 0.000 description 8
• 239000008272 agar Substances 0.000 description 8
• 108091008324 binding proteins Proteins 0.000 description 8
• 230000000875 corresponding effect Effects 0.000 description 8
• 239000012634 fragment Substances 0.000 description 8
• 230000002519 immonomodulatory effect Effects 0.000 description 8
• 230000001900 immune effect Effects 0.000 description 8
• 230000003993 interaction Effects 0.000 description 8
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
• 239000003001 serine protease inhibitor Substances 0.000 description 8
• 239000007901 soft capsule Substances 0.000 description 8
• 210000000952 spleen Anatomy 0.000 description 8
• 238000007619 statistical method Methods 0.000 description 8
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
• 239000000758 substrate Substances 0.000 description 8
• 230000032258 transport Effects 0.000 description 8
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 7
• 229940045513 CTLA4 antagonist Drugs 0.000 description 7
• 108700023372 Glycosyltransferases Proteins 0.000 description 7
• 102000051366 Glycosyltransferases Human genes 0.000 description 7
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 7
• 108090001007 Interleukin-8 Proteins 0.000 description 7
• 102000004890 Interleukin-8 Human genes 0.000 description 7
• 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 7
• 229920002472 Starch Polymers 0.000 description 7
• 230000009286 beneficial effect Effects 0.000 description 7
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
• 230000001332 colony forming effect Effects 0.000 description 7
• 239000000975 dye Substances 0.000 description 7
• 239000012636 effector Substances 0.000 description 7
• 239000000499 gel Substances 0.000 description 7
• 210000002443 helper t lymphocyte Anatomy 0.000 description 7
• 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 238000011201 multiple comparisons test Methods 0.000 description 7
• 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 7
• 230000009467 reduction Effects 0.000 description 7
• 210000004988 splenocyte Anatomy 0.000 description 7
• 239000007921 spray Substances 0.000 description 7
• 239000008107 starch Substances 0.000 description 7
• 235000019698 starch Nutrition 0.000 description 7
• 239000000126 substance Substances 0.000 description 7
• 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 6
• 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 6
• 108091006112 ATPases Proteins 0.000 description 6
• 102000057290 Adenosine Triphosphatases Human genes 0.000 description 6
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
• 241001608472 Bifidobacterium longum Species 0.000 description 6
• 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 6
• 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 6
• 108010078791 Carrier Proteins Proteins 0.000 description 6
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
• 206010015548 Euthanasia Diseases 0.000 description 6
• 206010017964 Gastrointestinal infection Diseases 0.000 description 6
• 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 6
• 229930182816 L-glutamine Natural products 0.000 description 6
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
• RMINQIRDFIBNLE-NNRWGFCXSA-N O-[N-acetyl-alpha-neuraminyl-(2->6)-N-acetyl-alpha-D-galactosaminyl]-L-serine Chemical compound O1[C@H](OC[C@H](N)C(O)=O)[C@H](NC(=O)C)[C@@H](O)[C@@H](O)[C@H]1CO[C@@]1(C(O)=O)O[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C1 RMINQIRDFIBNLE-NNRWGFCXSA-N 0.000 description 6
• 239000004698 Polyethylene Substances 0.000 description 6
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 6
• 102100038358 Prostate-specific antigen Human genes 0.000 description 6
• 238000011529 RT qPCR Methods 0.000 description 6
• 102000002278 Ribosomal Proteins Human genes 0.000 description 6
• 108010000605 Ribosomal Proteins Proteins 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• 108700025700 Wilms Tumor Genes Proteins 0.000 description 6
• 235000001014 amino acid Nutrition 0.000 description 6
• 150000001413 amino acids Chemical class 0.000 description 6
• 230000000259 anti-tumor effect Effects 0.000 description 6
• 244000052616 bacterial pathogen Species 0.000 description 6
• 230000037396 body weight Effects 0.000 description 6
• 238000005119 centrifugation Methods 0.000 description 6
• 208000019836 digestive system infectious disease Diseases 0.000 description 6
• 239000003937 drug carrier Substances 0.000 description 6
• 238000005516 engineering process Methods 0.000 description 6
• 230000006870 function Effects 0.000 description 6
• 229920000159 gelatin Polymers 0.000 description 6
• 239000008273 gelatin Substances 0.000 description 6
• 150000004676 glycans Chemical class 0.000 description 6
• 238000011534 incubation Methods 0.000 description 6
• 230000006698 induction Effects 0.000 description 6
• 238000002347 injection Methods 0.000 description 6
• 239000007924 injection Substances 0.000 description 6
• 230000015788 innate immune response Effects 0.000 description 6
• 239000008101 lactose Substances 0.000 description 6
• 229960001375 lactose Drugs 0.000 description 6
• 230000000813 microbial effect Effects 0.000 description 6
• 230000004048 modification Effects 0.000 description 6
• 238000012986 modification Methods 0.000 description 6
• 235000016709 nutrition Nutrition 0.000 description 6
• 230000001717 pathogenic effect Effects 0.000 description 6
• 229920001282 polysaccharide Polymers 0.000 description 6
• 239000005017 polysaccharide Substances 0.000 description 6
• 235000013406 prebiotics Nutrition 0.000 description 6
• 230000008569 process Effects 0.000 description 6
• 238000012163 sequencing technique Methods 0.000 description 6
• 239000007787 solid Substances 0.000 description 6
• 210000004881 tumor cell Anatomy 0.000 description 6
• 108010058432 Chaperonin 60 Proteins 0.000 description 5
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
• 102000006465 DNA Restriction-Modification Enzymes Human genes 0.000 description 5
• 108010044289 DNA Restriction-Modification Enzymes Proteins 0.000 description 5
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 5
• 108010010803 Gelatin Proteins 0.000 description 5
• 102000003886 Glycoproteins Human genes 0.000 description 5
• 108090000288 Glycoproteins Proteins 0.000 description 5
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 5
• 102100037850 Interferon gamma Human genes 0.000 description 5
• 108010074328 Interferon-gamma Proteins 0.000 description 5
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
• LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 5
• 102000003939 Membrane transport proteins Human genes 0.000 description 5
• 108090000301 Membrane transport proteins Proteins 0.000 description 5
• 229930006000 Sucrose Natural products 0.000 description 5
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
• 210000000447 Th1 cell Anatomy 0.000 description 5
• 239000005862 Whey Substances 0.000 description 5
• 108010046377 Whey Proteins Proteins 0.000 description 5
• 102000007544 Whey Proteins Human genes 0.000 description 5
• 239000000853 adhesive Substances 0.000 description 5
• 230000001070 adhesive effect Effects 0.000 description 5
• 235000004279 alanine Nutrition 0.000 description 5
• 230000015572 biosynthetic process Effects 0.000 description 5
• 230000024245 cell differentiation Effects 0.000 description 5
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
• 230000004069 differentiation Effects 0.000 description 5
• 238000009826 distribution Methods 0.000 description 5
• 239000003814 drug Substances 0.000 description 5
• 230000002708 enhancing effect Effects 0.000 description 5
• 238000009505 enteric coating Methods 0.000 description 5
• 239000002702 enteric coating Substances 0.000 description 5
• 230000002496 gastric effect Effects 0.000 description 5
• 235000019322 gelatine Nutrition 0.000 description 5
• 235000011852 gelatine desserts Nutrition 0.000 description 5
• 235000011187 glycerol Nutrition 0.000 description 5
• 108010050848 glycylleucine Proteins 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 230000002757 inflammatory effect Effects 0.000 description 5
• 230000005764 inhibitory process Effects 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 210000004185 liver Anatomy 0.000 description 5
• 239000011159 matrix material Substances 0.000 description 5
• 235000013336 milk Nutrition 0.000 description 5
• 239000008267 milk Substances 0.000 description 5
• 210000004080 milk Anatomy 0.000 description 5
• 238000012544 monitoring process Methods 0.000 description 5
• 238000002170 nanoflow liquid chromatography-tandem mass spectrometry Methods 0.000 description 5
• 239000002773 nucleotide Substances 0.000 description 5
• 125000003729 nucleotide group Chemical group 0.000 description 5
• 101150077915 oppA gene Proteins 0.000 description 5
• 229920001223 polyethylene glycol Polymers 0.000 description 5
• 229920001184 polypeptide Polymers 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 239000006041 probiotic Substances 0.000 description 5
• 230000000529 probiotic effect Effects 0.000 description 5
• 235000018291 probiotics Nutrition 0.000 description 5
• 230000001681 protective effect Effects 0.000 description 5
• 239000000243 solution Substances 0.000 description 5
• 235000010356 sorbitol Nutrition 0.000 description 5
• 239000000600 sorbitol Substances 0.000 description 5
• 238000001228 spectrum Methods 0.000 description 5
• 229960005322 streptomycin Drugs 0.000 description 5
• 239000005720 sucrose Substances 0.000 description 5
• 235000000346 sugar Nutrition 0.000 description 5
• 239000013589 supplement Substances 0.000 description 5
• 239000007169 ycfa-medium Substances 0.000 description 5
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
• 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 4
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 4
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 4
• 206010002091 Anaesthesia Diseases 0.000 description 4
• 238000011740 C57BL/6 mouse Methods 0.000 description 4
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
• 239000004471 Glycine Substances 0.000 description 4
• 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 4
• OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 4
• 229930195725 Mannitol Natural products 0.000 description 4
• 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 4
• 230000005867 T cell response Effects 0.000 description 4
• 230000003213 activating effect Effects 0.000 description 4
• 239000002671 adjuvant Substances 0.000 description 4
• 230000037005 anaesthesia Effects 0.000 description 4
• 230000003110 anti-inflammatory effect Effects 0.000 description 4
• 230000005875 antibody response Effects 0.000 description 4
• 230000036755 cellular response Effects 0.000 description 4
• 239000003795 chemical substances by application Substances 0.000 description 4
• 150000001875 compounds Chemical class 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 238000010586 diagram Methods 0.000 description 4
• 208000035475 disorder Diseases 0.000 description 4
• 238000005538 encapsulation Methods 0.000 description 4
• 239000002158 endotoxin Substances 0.000 description 4
• 230000007613 environmental effect Effects 0.000 description 4
• 230000002255 enzymatic effect Effects 0.000 description 4
• 229940088598 enzyme Drugs 0.000 description 4
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
• 244000005709 gut microbiome Species 0.000 description 4
• BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
• 238000011081 inoculation Methods 0.000 description 4
• 235000020778 linoleic acid Nutrition 0.000 description 4
• OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 4
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
• 238000009630 liquid culture Methods 0.000 description 4
• 235000019359 magnesium stearate Nutrition 0.000 description 4
• 239000000594 mannitol Substances 0.000 description 4
• 235000010355 mannitol Nutrition 0.000 description 4
• 239000003550 marker Substances 0.000 description 4
• 210000002901 mesenchymal stem cell Anatomy 0.000 description 4
• 230000002503 metabolic effect Effects 0.000 description 4
• 238000010172 mouse model Methods 0.000 description 4
• 229920001542 oligosaccharide Polymers 0.000 description 4
• 229940127240 opiate Drugs 0.000 description 4
• 229920000642 polymer Polymers 0.000 description 4
• 239000002243 precursor Substances 0.000 description 4
• 239000003755 preservative agent Substances 0.000 description 4
• 108091008146 restriction endonucleases Proteins 0.000 description 4
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 4
• 239000004299 sodium benzoate Substances 0.000 description 4
• 235000010234 sodium benzoate Nutrition 0.000 description 4
• 238000010186 staining Methods 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• 239000003826 tablet Substances 0.000 description 4
• 101150011891 tadA gene Proteins 0.000 description 4
• 230000002103 transcriptional effect Effects 0.000 description 4
• 230000003612 virological effect Effects 0.000 description 4
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 3
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• 241000203069 Archaea Species 0.000 description 3
• 239000004475 Arginine Substances 0.000 description 3
• 208000023275 Autoimmune disease Diseases 0.000 description 3
• GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 3
• 102100026189 Beta-galactosidase Human genes 0.000 description 3
• 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 3
• 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 3
• SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
• 229920002527 Glycogen Polymers 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 3
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
• 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 3
• 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 3
• 102000004157 Hydrolases Human genes 0.000 description 3
• 108090000604 Hydrolases Proteins 0.000 description 3
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
• 108090000769 Isomerases Proteins 0.000 description 3
• 102000004195 Isomerases Human genes 0.000 description 3
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
• 240000007472 Leucaena leucocephala Species 0.000 description 3
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 241000736262 Microbiota Species 0.000 description 3
• 108010008707 Mucin-1 Proteins 0.000 description 3
• 102100034256 Mucin-1 Human genes 0.000 description 3
• 229930182555 Penicillin Natural products 0.000 description 3
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
• 108091000080 Phosphotransferase Proteins 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• 108010030975 Polyketide Synthases Proteins 0.000 description 3
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
• 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 3
• 101800000874 Small capsid protein Proteins 0.000 description 3
• 101800000996 Small capsid protein precursor Proteins 0.000 description 3
• 241000191967 Staphylococcus aureus Species 0.000 description 3
• 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 3
• 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 3
• 102100039360 Toll-like receptor 4 Human genes 0.000 description 3
• 102100039357 Toll-like receptor 5 Human genes 0.000 description 3
• 108091023040 Transcription factor Proteins 0.000 description 3
• 102000040945 Transcription factor Human genes 0.000 description 3
• 102000008579 Transposases Human genes 0.000 description 3
• 108010020764 Transposases Proteins 0.000 description 3
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 230000001464 adherent effect Effects 0.000 description 3
• 238000004220 aggregation Methods 0.000 description 3
• 230000032683 aging Effects 0.000 description 3
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
• 239000012298 atmosphere Substances 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 229940041514 candida albicans extract Drugs 0.000 description 3
• 230000023852 carbohydrate metabolic process Effects 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 239000006143 cell culture medium Substances 0.000 description 3
• 210000002421 cell wall Anatomy 0.000 description 3
• 108090000759 cellulose synthase (UDP-forming) Proteins 0.000 description 3
• 208000016532 chronic granulomatous disease Diseases 0.000 description 3
• 238000003776 cleavage reaction Methods 0.000 description 3
• 238000010367 cloning Methods 0.000 description 3
• 230000002950 deficient Effects 0.000 description 3
• 238000006731 degradation reaction Methods 0.000 description 3
• 235000005911 diet Nutrition 0.000 description 3
• 230000037213 diet Effects 0.000 description 3
• 230000029087 digestion Effects 0.000 description 3
• 210000003608 fece Anatomy 0.000 description 3
• 235000013350 formula milk Nutrition 0.000 description 3
• 238000004108 freeze drying Methods 0.000 description 3
• 230000004927 fusion Effects 0.000 description 3
• 229930182830 galactose Natural products 0.000 description 3
• 229940096919 glycogen Drugs 0.000 description 3
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
• 230000005965 immune activity Effects 0.000 description 3
• 210000002865 immune cell Anatomy 0.000 description 3
• 230000001939 inductive effect Effects 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 238000002743 insertional mutagenesis Methods 0.000 description 3
• 238000011068 loading method Methods 0.000 description 3
• 230000004807 localization Effects 0.000 description 3
• 230000004060 metabolic process Effects 0.000 description 3
• 229920000609 methyl cellulose Polymers 0.000 description 3
• 235000010981 methylcellulose Nutrition 0.000 description 3
• 239000001923 methylcellulose Substances 0.000 description 3
• 229960002715 nicotine Drugs 0.000 description 3
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 3
• 230000035764 nutrition Effects 0.000 description 3
• 108091008819 oncoproteins Proteins 0.000 description 3
• 102000027450 oncoproteins Human genes 0.000 description 3
• 230000003287 optical effect Effects 0.000 description 3
• 230000036407 pain Effects 0.000 description 3
• 244000052769 pathogen Species 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 229940049954 penicillin Drugs 0.000 description 3
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
• 102000020233 phosphotransferase Human genes 0.000 description 3
• 238000007747 plating Methods 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 235000021251 pulses Nutrition 0.000 description 3
• 238000011002 quantification Methods 0.000 description 3
• 108020003175 receptors Proteins 0.000 description 3
• 102000005962 receptors Human genes 0.000 description 3
• 230000007017 scission Effects 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 235000002639 sodium chloride Nutrition 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 235000021262 sour milk Nutrition 0.000 description 3
• 229960000268 spectinomycin Drugs 0.000 description 3
• UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 3
• 230000003068 static effect Effects 0.000 description 3
• 238000010254 subcutaneous injection Methods 0.000 description 3
• 239000007929 subcutaneous injection Substances 0.000 description 3
• 238000001356 surgical procedure Methods 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 102000013498 tau Proteins Human genes 0.000 description 3
• 108010026424 tau Proteins Proteins 0.000 description 3
• 210000001519 tissue Anatomy 0.000 description 3
• 238000004627 transmission electron microscopy Methods 0.000 description 3
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
• 238000002255 vaccination Methods 0.000 description 3
• 239000013598 vector Substances 0.000 description 3
• 238000005406 washing Methods 0.000 description 3
• 239000012138 yeast extract Substances 0.000 description 3
• 239000011701 zinc Substances 0.000 description 3
• 229910052725 zinc Inorganic materials 0.000 description 3
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
• XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 2
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
• 108030005610 2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylic-acid synthases Proteins 0.000 description 2
• LHYQAEFVHIZFLR-UHFFFAOYSA-L 4-(4-diazonio-3-methoxyphenyl)-2-methoxybenzenediazonium;dichloride Chemical compound [Cl-].[Cl-].C1=C([N+]#N)C(OC)=CC(C=2C=C(OC)C([N+]#N)=CC=2)=C1 LHYQAEFVHIZFLR-UHFFFAOYSA-L 0.000 description 2
• ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
• 150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 2
• OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
• 102000021527 ATP binding proteins Human genes 0.000 description 2
• 108091011108 ATP binding proteins Proteins 0.000 description 2
• 241000606750 Actinobacillus Species 0.000 description 2
• PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• 241001465677 Ancylostomatoidea Species 0.000 description 2
• 101100219315 Arabidopsis thaliana CYP83A1 gene Proteins 0.000 description 2
• 101100140581 Arabidopsis thaliana REF6 gene Proteins 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 241000416162 Astragalus gummifer Species 0.000 description 2
• 241000193738 Bacillus anthracis Species 0.000 description 2
• 244000063299 Bacillus subtilis Species 0.000 description 2
• 241001655328 Bifidobacteriales Species 0.000 description 2
• 241000186016 Bifidobacterium bifidum Species 0.000 description 2
• 241000741973 Bifidobacterium breve DSM 20213 = JCM 1192 Species 0.000 description 2
• 101100439426 Bradyrhizobium diazoefficiens (strain JCM 10833 / BCRC 13528 / IAM 13628 / NBRC 14792 / USDA 110) groEL4 gene Proteins 0.000 description 2
• 201000010717 Bruton-type agammaglobulinemia Diseases 0.000 description 2
• 238000011357 CAR T-cell therapy Methods 0.000 description 2
• 206010006895 Cachexia Diseases 0.000 description 2
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
• 201000009030 Carcinoma Diseases 0.000 description 2
• 108010022172 Chitinases Proteins 0.000 description 2
• 102000012286 Chitinases Human genes 0.000 description 2
• 241000606161 Chlamydia Species 0.000 description 2
• 108010000231 Choloylglycine hydrolase Proteins 0.000 description 2
• WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 2
• 241000193403 Clostridium Species 0.000 description 2
• 241000193470 Clostridium sporogenes Species 0.000 description 2
• 208000015943 Coeliac disease Diseases 0.000 description 2
• 201000003874 Common Variable Immunodeficiency Diseases 0.000 description 2
• 241000701022 Cytomegalovirus Species 0.000 description 2
• GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 2
• NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 2
• QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 2
• SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
• FNZLKVNUWIIPSJ-RFZPGFLSSA-N D-xylulose 5-phosphate Chemical compound OCC(=O)[C@@H](O)[C@H](O)COP(O)(O)=O FNZLKVNUWIIPSJ-RFZPGFLSSA-N 0.000 description 2
• 108010058076 D-xylulose reductase Proteins 0.000 description 2
• 230000007023 DNA restriction-modification system Effects 0.000 description 2
• 102100037373 DNA-(apurinic or apyrimidinic site) endonuclease Human genes 0.000 description 2
• 102100027887 Deaminated glutathione amidase Human genes 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
• 108090000156 Fructokinases Proteins 0.000 description 2
• 229930091371 Fructose Natural products 0.000 description 2
• 239000005715 Fructose Substances 0.000 description 2
• PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
• 108090000926 GMP synthase (glutamine-hydrolyzing) Proteins 0.000 description 2
• 102100033452 GMP synthase [glutamine-hydrolyzing] Human genes 0.000 description 2
• VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 2
• 241000700721 Hepatitis B virus Species 0.000 description 2
• 101000806846 Homo sapiens DNA-(apurinic or apyrimidinic site) endonuclease Proteins 0.000 description 2
• 101000632167 Homo sapiens Deaminated glutathione amidase Proteins 0.000 description 2
• 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 2
• 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 2
• 101000996087 Homo sapiens Omega-amidase NIT2 Proteins 0.000 description 2
• 101000835083 Homo sapiens Tissue factor pathway inhibitor 2 Proteins 0.000 description 2
• 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
• 241000701806 Human papillomavirus Species 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 206010061598 Immunodeficiency Diseases 0.000 description 2
• 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 2
• 229920001202 Inulin Polymers 0.000 description 2
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• 108010009384 L-Iditol 2-Dehydrogenase Proteins 0.000 description 2
• SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
• 241000186660 Lactobacillus Species 0.000 description 2
• 240000006024 Lactobacillus plantarum Species 0.000 description 2
• 241000186779 Listeria monocytogenes Species 0.000 description 2
• 238000000134 MTT assay Methods 0.000 description 2
• 231100000002 MTT assay Toxicity 0.000 description 2
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
• 229920002774 Maltodextrin Polymers 0.000 description 2
• 239000005913 Maltodextrin Substances 0.000 description 2
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
• 102000007557 Melanoma-Specific Antigens Human genes 0.000 description 2
• 108010071463 Melanoma-Specific Antigens Proteins 0.000 description 2
• 108010006519 Molecular Chaperones Proteins 0.000 description 2
• 108010063954 Mucins Proteins 0.000 description 2
• 101100269674 Mus musculus Alyref2 gene Proteins 0.000 description 2
• 241000186359 Mycobacterium Species 0.000 description 2
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
• OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
• OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
• MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
• 108010057466 NF-kappa B Proteins 0.000 description 2
• 102000003945 NF-kappa B Human genes 0.000 description 2
• 241000588650 Neisseria meningitidis Species 0.000 description 2
• 101000996085 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) Nitrogen catabolic enzyme regulatory protein Proteins 0.000 description 2
• 108010053775 Nisin Proteins 0.000 description 2
• NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 2
• 208000031662 Noncommunicable disease Diseases 0.000 description 2
• 108091028043 Nucleic acid sequence Proteins 0.000 description 2
• AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 2
• 102100034446 Omega-amidase NIT2 Human genes 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 102000013566 Plasminogen Human genes 0.000 description 2
• 108010051456 Plasminogen Proteins 0.000 description 2
• DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
• 108010026552 Proteome Proteins 0.000 description 2
• 208000032536 Pseudomonas Infections Diseases 0.000 description 2
• 238000011530 RNeasy Mini Kit Methods 0.000 description 2
• 239000012979 RPMI medium Substances 0.000 description 2
• 206010037742 Rabies Diseases 0.000 description 2
• 208000035415 Reinfection Diseases 0.000 description 2
• 241000725643 Respiratory syncytial virus Species 0.000 description 2
• 241000315672 SARS coronavirus Species 0.000 description 2
• 101100140580 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) REF2 gene Proteins 0.000 description 2
• NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 2
• 241000607142 Salmonella Species 0.000 description 2
• 241001138501 Salmonella enterica Species 0.000 description 2
• 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 2
• 101001010097 Shigella phage SfV Bactoprenol-linked glucose translocase Proteins 0.000 description 2
• 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 2
• 241000700584 Simplexvirus Species 0.000 description 2
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 2
• 102100026974 Sorbitol dehydrogenase Human genes 0.000 description 2
• 241000194017 Streptococcus Species 0.000 description 2
• 244000057717 Streptococcus lactis Species 0.000 description 2
• 241000193998 Streptococcus pneumoniae Species 0.000 description 2
• 241000193996 Streptococcus pyogenes Species 0.000 description 2
• 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 2
• 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 2
• 229920001615 Tragacanth Polymers 0.000 description 2
• 108010043652 Transketolase Proteins 0.000 description 2
• 102000014701 Transketolase Human genes 0.000 description 2
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
• DRQXUCVJDCRJDB-UHFFFAOYSA-N Turanose Natural products OC1C(CO)OC(O)(CO)C1OC1C(O)C(O)C(O)C(CO)O1 DRQXUCVJDCRJDB-UHFFFAOYSA-N 0.000 description 2
• 108010046334 Urease Proteins 0.000 description 2
• 208000016349 X-linked agammaglobulinemia Diseases 0.000 description 2
• TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
• 240000008042 Zea mays Species 0.000 description 2
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 230000033289 adaptive immune response Effects 0.000 description 2
• 210000005006 adaptive immune system Anatomy 0.000 description 2
• 239000011543 agarose gel Substances 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
• NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 2
• 239000003708 ampul Substances 0.000 description 2
• 229940089837 amygdalin Drugs 0.000 description 2
• YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 2
• 230000003625 amylolytic effect Effects 0.000 description 2
• 230000003698 anagen phase Effects 0.000 description 2
• 230000036592 analgesia Effects 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 235000006708 antioxidants Nutrition 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 229960000271 arbutin Drugs 0.000 description 2
• 229940065181 bacillus anthracis Drugs 0.000 description 2
• 230000010065 bacterial adhesion Effects 0.000 description 2
• GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
• DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 2
• 235000013361 beverage Nutrition 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 229960000074 biopharmaceutical Drugs 0.000 description 2
• 229960002685 biotin Drugs 0.000 description 2
• 235000020958 biotin Nutrition 0.000 description 2
• 239000011616 biotin Substances 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
• IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 2
• 229960003184 carprofen Drugs 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 108010079058 casein hydrolysate Proteins 0.000 description 2
• 230000020411 cell activation Effects 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 238000007621 cluster analysis Methods 0.000 description 2
• 239000011248 coating agent Substances 0.000 description 2
• 238000010835 comparative analysis Methods 0.000 description 2
• 230000000052 comparative effect Effects 0.000 description 2
• 230000000295 complement effect Effects 0.000 description 2
• 235000005822 corn Nutrition 0.000 description 2
• 235000020247 cow milk Nutrition 0.000 description 2
• 108010032220 cyclomaltodextrinase Proteins 0.000 description 2
• 230000009089 cytolysis Effects 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 230000002354 daily effect Effects 0.000 description 2
• 235000013365 dairy product Nutrition 0.000 description 2
• 238000007405 data analysis Methods 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 235000015872 dietary supplement Nutrition 0.000 description 2
• 238000009792 diffusion process Methods 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 229940000406 drug candidate Drugs 0.000 description 2
• XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 2
• 229940093496 esculin Drugs 0.000 description 2
• AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 2
• 239000003797 essential amino acid Substances 0.000 description 2
• 235000020776 essential amino acid Nutrition 0.000 description 2
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
• YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 2
• 238000010195 expression analysis Methods 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 150000004665 fatty acids Chemical class 0.000 description 2
• 239000000835 fiber Substances 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 230000002538 fungal effect Effects 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 2
• 235000001727 glucose Nutrition 0.000 description 2
• 230000002414 glycolytic effect Effects 0.000 description 2
• 125000003147 glycosyl group Chemical group 0.000 description 2
• 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 101150077981 groEL gene Proteins 0.000 description 2
• 239000007902 hard capsule Substances 0.000 description 2
• 230000005934 immune activation Effects 0.000 description 2
• 238000003018 immunoassay Methods 0.000 description 2
• 230000007813 immunodeficiency Effects 0.000 description 2
• 238000002513 implantation Methods 0.000 description 2
• 208000027866 inflammatory disease Diseases 0.000 description 2
• 206010022000 influenza Diseases 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 239000002054 inoculum Substances 0.000 description 2
• 230000000968 intestinal effect Effects 0.000 description 2
• JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
• 229940029339 inulin Drugs 0.000 description 2
• PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
• PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
• 229960002725 isoflurane Drugs 0.000 description 2
• 229940039696 lactobacillus Drugs 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 101150078797 luxS gene Proteins 0.000 description 2
• 230000002934 lysing effect Effects 0.000 description 2
• 201000004792 malaria Diseases 0.000 description 2
• 229940035034 maltodextrin Drugs 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• HOVAGTYPODGVJG-ZFYZTMLRSA-N methyl alpha-D-glucopyranoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HOVAGTYPODGVJG-ZFYZTMLRSA-N 0.000 description 2
• HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 2
• 230000011987 methylation Effects 0.000 description 2
• 238000007069 methylation reaction Methods 0.000 description 2
• 239000002480 mineral oil Substances 0.000 description 2
• 235000010446 mineral oil Nutrition 0.000 description 2
• 238000007837 multiplex assay Methods 0.000 description 2
• 229950006780 n-acetylglucosamine Drugs 0.000 description 2
• 230000004770 neurodegeneration Effects 0.000 description 2
• 208000015122 neurodegenerative disease Diseases 0.000 description 2
• 239000004309 nisin Substances 0.000 description 2
• 235000010297 nisin Nutrition 0.000 description 2
• 235000015097 nutrients Nutrition 0.000 description 2
• 102000005549 oligoribonuclease Human genes 0.000 description 2
• 108020002020 oligoribonuclease Proteins 0.000 description 2
• 238000003305 oral gavage Methods 0.000 description 2
• BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
• 230000003071 parasitic effect Effects 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 108010050430 phosphoglycolate phosphatase Proteins 0.000 description 2
• 108010004621 phosphoketolase Proteins 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 230000003334 potential effect Effects 0.000 description 2
• 230000002335 preservative effect Effects 0.000 description 2
• NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
• 238000003259 recombinant expression Methods 0.000 description 2
• 239000013558 reference substance Substances 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 2
• 229940120668 salicin Drugs 0.000 description 2
• 238000007790 scraping Methods 0.000 description 2
• 238000010845 search algorithm Methods 0.000 description 2
• 210000000813 small intestine Anatomy 0.000 description 2
• 235000015424 sodium Nutrition 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 239000001632 sodium acetate Substances 0.000 description 2
• 235000017281 sodium acetate Nutrition 0.000 description 2
• 229960003885 sodium benzoate Drugs 0.000 description 2
• 239000004334 sorbic acid Substances 0.000 description 2
• 235000010199 sorbic acid Nutrition 0.000 description 2
• 229940075582 sorbic acid Drugs 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 2
• 108091012369 thiamine pyrophosphate binding proteins Proteins 0.000 description 2
• 102000022046 thiamine pyrophosphate binding proteins Human genes 0.000 description 2
• 235000010487 tragacanth Nutrition 0.000 description 2
• 239000000196 tragacanth Substances 0.000 description 2
• 229940116362 tragacanth Drugs 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• 230000014616 translation Effects 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 description 2
• 210000004291 uterus Anatomy 0.000 description 2
• 239000000811 xylitol Substances 0.000 description 2
• 235000010447 xylitol Nutrition 0.000 description 2
• HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
• 229960002675 xylitol Drugs 0.000 description 2
• 229930195724 β-lactose Natural products 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• OEDPHAKKZGDBEV-GFPBKZJXSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2r)-3-[2,3-di(hexadecanoyloxy)propylsulfanyl]-2-(hexadecanoylamino)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CCCCCCCCCCCCCCC)CSCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC OEDPHAKKZGDBEV-GFPBKZJXSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
• KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• 206010000060 Abdominal distension Diseases 0.000 description 1
• 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
• 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 102100026277 Alpha-galactosidase A Human genes 0.000 description 1
• 101001094887 Ambrosia artemisiifolia Pectate lyase 1 Proteins 0.000 description 1
• 101001123576 Ambrosia artemisiifolia Pectate lyase 2 Proteins 0.000 description 1
• 101001123572 Ambrosia artemisiifolia Pectate lyase 3 Proteins 0.000 description 1
• 101000573177 Ambrosia artemisiifolia Pectate lyase 5 Proteins 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
• 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
• 208000019901 Anxiety disease Diseases 0.000 description 1
• 102100024365 Arf-GAP domain and FG repeat-containing protein 1 Human genes 0.000 description 1
• 244000075850 Avena orientalis Species 0.000 description 1
• 235000007319 Avena orientalis Nutrition 0.000 description 1
• 235000007558 Avena sp Nutrition 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 238000011731 BALB/cByJ (JAX™ mouse strain) Methods 0.000 description 1
• 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
• 241000193830 Bacillus <bacterium> Species 0.000 description 1
• 101100301559 Bacillus anthracis repS gene Proteins 0.000 description 1
• 208000034309 Bacterial disease carrier Diseases 0.000 description 1
• 108010062877 Bacteriocins Proteins 0.000 description 1
• 241000605059 Bacteroidetes Species 0.000 description 1
• 101000971127 Bartonella henselae Autotransporter adhesin BadA Proteins 0.000 description 1
• 229920002498 Beta-glucan Polymers 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 241000003117 Bifidobacterium breve UCC2003 Species 0.000 description 1
• 241001213452 Bifidobacterium longum NCC2705 Species 0.000 description 1
• 241001202853 Blautia Species 0.000 description 1
• 241001416152 Bos frontalis Species 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• 108010074051 C-Reactive Protein Proteins 0.000 description 1
• 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
• 102100032752 C-reactive protein Human genes 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 241001631457 Cannula Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 108010076119 Caseins Proteins 0.000 description 1
• 108010078140 Cation Transport Proteins Proteins 0.000 description 1
• 240000008886 Ceratonia siliqua Species 0.000 description 1
• 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
• 102000006303 Chaperonin 60 Human genes 0.000 description 1
• 108010055166 Chemokine CCL5 Proteins 0.000 description 1
• 102000001327 Chemokine CCL5 Human genes 0.000 description 1
• 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
• 206010061041 Chlamydial infection Diseases 0.000 description 1
• 241000511343 Chondrostoma nasus Species 0.000 description 1
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
• 241000207199 Citrus Species 0.000 description 1
• 241001112695 Clostridiales Species 0.000 description 1
• 101100247969 Clostridium saccharobutylicum regA gene Proteins 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 206010010099 Combined immunodeficiency Diseases 0.000 description 1
• 108091035707 Consensus sequence Proteins 0.000 description 1
• 206010010904 Convulsion Diseases 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
• LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 1
• HMFHBZSHGGEWLO-IOVATXLUSA-N D-xylofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H]1O HMFHBZSHGGEWLO-IOVATXLUSA-N 0.000 description 1
• 102000003844 DNA helicases Human genes 0.000 description 1
• 108090000133 DNA helicases Proteins 0.000 description 1
• 208000005156 Dehydration Diseases 0.000 description 1
• 102000016911 Deoxyribonucleases Human genes 0.000 description 1
• 108010053770 Deoxyribonucleases Proteins 0.000 description 1
• 108010016626 Dipeptides Proteins 0.000 description 1
• 101001134680 Drosophila melanogaster POU domain protein 2, isoform A Proteins 0.000 description 1
• 101001134679 Drosophila melanogaster POU domain protein 2, isoform B Proteins 0.000 description 1
• 101100082633 Drosophila melanogaster nub gene Proteins 0.000 description 1
• 101001134678 Drosophila virilis POU domain protein 2 Proteins 0.000 description 1
• 206010013975 Dyspnoeas Diseases 0.000 description 1
• 108010067770 Endopeptidase K Proteins 0.000 description 1
• 206010001427 Enterobacter infections Diseases 0.000 description 1
• 241000194033 Enterococcus Species 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000588722 Escherichia Species 0.000 description 1
• 101100412434 Escherichia coli (strain K12) repB gene Proteins 0.000 description 1
• 206010015719 Exsanguination Diseases 0.000 description 1
• 108010039731 Fatty Acid Synthases Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 241000192125 Firmicutes Species 0.000 description 1
• 101001076781 Fructilactobacillus sanfranciscensis (strain ATCC 27651 / DSM 20451 / JCM 5668 / CCUG 30143 / KCTC 3205 / NCIMB 702811 / NRRL B-3934 / L-12) Ribose-5-phosphate isomerase A Proteins 0.000 description 1
• 102000003793 Fructokinases Human genes 0.000 description 1
• 102000002464 Galactosidases Human genes 0.000 description 1
• 108010093031 Galactosidases Proteins 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• 102100038261 Glycerol-3-phosphate phosphatase Human genes 0.000 description 1
• 206010018612 Gonorrhoea Diseases 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 206010061190 Haemophilus infection Diseases 0.000 description 1
• 239000012981 Hank's balanced salt solution Substances 0.000 description 1
• 206010019375 Helicobacter infections Diseases 0.000 description 1
• 241000590002 Helicobacter pylori Species 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 1
• 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 1
• 101000605403 Homo sapiens Plasminogen Proteins 0.000 description 1
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
• 108010034143 Inflammasomes Proteins 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102100030703 Interleukin-22 Human genes 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 102100026236 Interleukin-8 Human genes 0.000 description 1
• 239000007836 KH2PO4 Substances 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• 241000588748 Klebsiella Species 0.000 description 1
• 206010061259 Klebsiella infection Diseases 0.000 description 1
• 241000588747 Klebsiella pneumoniae Species 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
• PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
• 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
• 206010024179 Legionella infections Diseases 0.000 description 1
• 208000007764 Legionnaires' Disease Diseases 0.000 description 1
• 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 239000006142 Luria-Bertani Agar Substances 0.000 description 1
• 239000006137 Luria-Bertani broth Substances 0.000 description 1
• 102000004317 Lyases Human genes 0.000 description 1
• 108090000856 Lyases Proteins 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 206010025280 Lymphocytosis Diseases 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 208000002720 Malnutrition Diseases 0.000 description 1
• 101710105799 Membrane-bound lytic murein transglycosylase D Proteins 0.000 description 1
• 208000034762 Meningococcal Infections Diseases 0.000 description 1
• 241000699673 Mesocricetus auratus Species 0.000 description 1
• 108060004795 Methyltransferase Proteins 0.000 description 1
• 102000016397 Methyltransferase Human genes 0.000 description 1
• 102000005431 Molecular Chaperones Human genes 0.000 description 1
• 241000588655 Moraxella catarrhalis Species 0.000 description 1
• 108010014251 Muramidase Proteins 0.000 description 1
• 102000016943 Muramidase Human genes 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 101100463616 Mus musculus Pfkl gene Proteins 0.000 description 1
• OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
• 101710154493 NADH-dependent butanol dehydrogenase A Proteins 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 229940123973 Oxygen scavenger Drugs 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 238000010222 PCR analysis Methods 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 206010033971 Paratyphoid fever Diseases 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 108010086950 Phosphoribosylanthranilate isomerase Proteins 0.000 description 1
• 206010035148 Plague Diseases 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 229920001100 Polydextrose Polymers 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000031951 Primary immunodeficiency Diseases 0.000 description 1
• 241000588770 Proteus mirabilis Species 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
• 239000013614 RNA sample Substances 0.000 description 1
• 238000003559 RNA-seq method Methods 0.000 description 1
• 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
• PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
• 229920000294 Resistant starch Polymers 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 102100020783 Ribokinase Human genes 0.000 description 1
• 102000046755 Ribokinases Human genes 0.000 description 1
• 108700006309 Ribokinases Proteins 0.000 description 1
• 108020001027 Ribosomal DNA Proteins 0.000 description 1
• 108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• CZMRCDWAGMRECN-UHFFFAOYSA-N Rohrzucker Natural products OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
• 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
• 102000030899 Serine-Type D-Ala-D-Ala Carboxypeptidase Human genes 0.000 description 1
• 108010004832 Serine-Type D-Ala-D-Ala Carboxypeptidase Proteins 0.000 description 1
• 102100023230 Serine/threonine-protein kinase MAK Human genes 0.000 description 1
• 206010061512 Serratia infection Diseases 0.000 description 1
• 101100114425 Streptococcus agalactiae copG gene Proteins 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 108090000088 Symporters Proteins 0.000 description 1
• 102000003673 Symporters Human genes 0.000 description 1
• 239000008051 TBE buffer Substances 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 240000006474 Theobroma bicolor Species 0.000 description 1
• 101150009046 Tnfrsf1a gene Proteins 0.000 description 1
• 102000002689 Toll-like receptor Human genes 0.000 description 1
• 108020000411 Toll-like receptor Proteins 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 241001148134 Veillonella Species 0.000 description 1
• 229930003268 Vitamin C Natural products 0.000 description 1
• 101000872823 Xenopus laevis Probable histone deacetylase 1-A Proteins 0.000 description 1
• 108010084455 Zeocin Proteins 0.000 description 1
• 238000002679 ablation Methods 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 102000005421 acetyltransferase Human genes 0.000 description 1
• 108020002494 acetyltransferase Proteins 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000007059 acute toxicity Effects 0.000 description 1
• 231100000403 acute toxicity Toxicity 0.000 description 1
• 230000000240 adjuvant effect Effects 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• 239000000956 alloy Substances 0.000 description 1
• 229910045601 alloy Inorganic materials 0.000 description 1
• WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 229960004050 aminobenzoic acid Drugs 0.000 description 1
• 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
• 239000001099 ammonium carbonate Substances 0.000 description 1
• 235000018660 ammonium molybdate Nutrition 0.000 description 1
• 239000011609 ammonium molybdate Substances 0.000 description 1
• APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
• 229940010552 ammonium molybdate Drugs 0.000 description 1
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
• 235000011130 ammonium sulphate Nutrition 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 229960004977 anhydrous lactose Drugs 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000001857 anti-mycotic effect Effects 0.000 description 1
• 239000012984 antibiotic solution Substances 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 239000002543 antimycotic Substances 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 230000005775 apoptotic pathway Effects 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 108010054176 apotransferrin Proteins 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
• 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
• 238000010876 biochemical test Methods 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 201000008275 breast carcinoma Diseases 0.000 description 1
• 238000011095 buffer preparation Methods 0.000 description 1
• RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
• 229960001736 buprenorphine Drugs 0.000 description 1
• 235000015155 buttermilk Nutrition 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 235000011148 calcium chloride Nutrition 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 229940105329 carboxymethylcellulose Drugs 0.000 description 1
• 230000001625 cardiomyogenic effect Effects 0.000 description 1
• 239000005018 casein Substances 0.000 description 1
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
• 235000021240 caseins Nutrition 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 230000030570 cellular localization Effects 0.000 description 1
• 231100000481 chemical toxicant Toxicity 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 235000015111 chews Nutrition 0.000 description 1
• 229960005091 chloramphenicol Drugs 0.000 description 1
• WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
• 229960005004 cholera vaccine Drugs 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 239000013611 chromosomal DNA Substances 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 230000007665 chronic toxicity Effects 0.000 description 1
• 231100000160 chronic toxicity Toxicity 0.000 description 1
• 235000020971 citrus fruits Nutrition 0.000 description 1
• 238000004140 cleaning Methods 0.000 description 1
• 238000003501 co-culture Methods 0.000 description 1
• 239000012881 co-culture medium Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• ASARMUCNOOHMLO-WLORSUFZSA-L cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ASARMUCNOOHMLO-WLORSUFZSA-L 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 230000001609 comparable effect Effects 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 235000020186 condensed milk Nutrition 0.000 description 1
• 235000009508 confectionery Nutrition 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 230000036461 convulsion Effects 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 238000005138 cryopreservation Methods 0.000 description 1
• 238000012364 cultivation method Methods 0.000 description 1
• 235000015140 cultured milk Nutrition 0.000 description 1
• 235000014048 cultured milk product Nutrition 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 230000001085 cytostatic effect Effects 0.000 description 1
• 230000018044 dehydration Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 230000035617 depilation Effects 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
• 235000019797 dipotassium phosphate Nutrition 0.000 description 1
• 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
• BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 230000007140 dysbiosis Effects 0.000 description 1
• 210000003162 effector t lymphocyte Anatomy 0.000 description 1
• 235000013601 eggs Nutrition 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 208000026500 emaciation Diseases 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 108091073357 enolase family Proteins 0.000 description 1
• 102000038676 enolase family Human genes 0.000 description 1
• 239000002662 enteric coated tablet Substances 0.000 description 1
• 230000006353 environmental stress Effects 0.000 description 1
• 230000003628 erosive effect Effects 0.000 description 1
• 229960003276 erythromycin Drugs 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 238000013401 experimental design Methods 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 230000001815 facial effect Effects 0.000 description 1
• 230000002550 fecal effect Effects 0.000 description 1
• 235000021001 fermented dairy product Nutrition 0.000 description 1
• 239000010408 film Substances 0.000 description 1
• 239000007888 film coating Substances 0.000 description 1
• 238000009501 film coating Methods 0.000 description 1
• 239000000834 fixative Substances 0.000 description 1
• 235000019541 flavored milk drink Nutrition 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 238000005189 flocculation Methods 0.000 description 1
• 230000016615 flocculation Effects 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 229960000304 folic acid Drugs 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 235000012041 food component Nutrition 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 108091008053 gene clusters Proteins 0.000 description 1
• 230000007614 genetic variation Effects 0.000 description 1
• 238000012268 genome sequencing Methods 0.000 description 1
• 238000003205 genotyping method Methods 0.000 description 1
• 235000020251 goat milk Nutrition 0.000 description 1
• 208000001786 gonorrhea Diseases 0.000 description 1
• 230000007773 growth pattern Effects 0.000 description 1
• 229940116364 hard fat Drugs 0.000 description 1
• 230000007407 health benefit Effects 0.000 description 1
• 230000003862 health status Effects 0.000 description 1
• 230000004217 heart function Effects 0.000 description 1
• 229940037467 helicobacter pylori Drugs 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 229940025294 hemin Drugs 0.000 description 1
• BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 230000007540 host microbe interaction Effects 0.000 description 1
• 102000057041 human TNF Human genes 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
• 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 230000002390 hyperplastic effect Effects 0.000 description 1
• 235000015243 ice cream Nutrition 0.000 description 1
• 230000008102 immune modulation Effects 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 230000004957 immunoregulator effect Effects 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 238000012405 in silico analysis Methods 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• ALDIVIWLBSDGGN-ONEGZZNKSA-N indigoidine Chemical compound O=C1NC(=O)C(N)=C\C1=C\1C(=O)NC(=O)C(N)=C/1 ALDIVIWLBSDGGN-ONEGZZNKSA-N 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 108010021103 inosine-uridine hydrolase Proteins 0.000 description 1
• 108010074109 interleukin-22 Proteins 0.000 description 1
• 208000024710 intermittent asthma Diseases 0.000 description 1
• 210000005027 intestinal barrier Anatomy 0.000 description 1
• 230000007358 intestinal barrier function Effects 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000010212 intracellular staining Methods 0.000 description 1
• 210000005024 intraepithelial lymphocyte Anatomy 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• UOEFDXYUEPHESS-QMGXLNLGSA-N isopropyl beta-D-galactopyranoside Chemical compound CC(C)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O UOEFDXYUEPHESS-QMGXLNLGSA-N 0.000 description 1
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
• 210000001630 jejunum Anatomy 0.000 description 1
• 229960000318 kanamycin Drugs 0.000 description 1
• 229930027917 kanamycin Natural products 0.000 description 1
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
• 229930182823 kanamycin A Natural products 0.000 description 1
• 229960003299 ketamine Drugs 0.000 description 1
• 229940072205 lactobacillus plantarum Drugs 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 230000037356 lipid metabolism Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 235000010335 lysozyme Nutrition 0.000 description 1
• 239000004325 lysozyme Substances 0.000 description 1
• 229960000274 lysozyme Drugs 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
• 235000019341 magnesium sulphate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000001071 malnutrition Effects 0.000 description 1
• 235000000824 malnutrition Nutrition 0.000 description 1
• 239000000845 maltitol Substances 0.000 description 1
• 235000010449 maltitol Nutrition 0.000 description 1
• VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
• 229940035436 maltitol Drugs 0.000 description 1
• 230000008774 maternal effect Effects 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 238000011133 mesenchymal stem cell therapy Methods 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 238000001000 micrograph Methods 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 239000012982 microporous membrane Substances 0.000 description 1
• 238000009343 monoculture Methods 0.000 description 1
• 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
• 235000019796 monopotassium phosphate Nutrition 0.000 description 1
• 230000003232 mucoadhesive effect Effects 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
• 210000000107 myocyte Anatomy 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 229940052778 neisseria meningitidis Drugs 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 235000021140 nondigestible carbohydrates Nutrition 0.000 description 1
• 208000015380 nutritional deficiency disease Diseases 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
• 244000039328 opportunistic pathogen Species 0.000 description 1
• 230000010355 oscillation Effects 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 210000003200 peritoneal cavity Anatomy 0.000 description 1
• 239000008024 pharmaceutical diluent Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• KCRZDTROFIOPBP-UHFFFAOYSA-N phosphono 2,3-dihydroxypropanoate Chemical compound OCC(O)C(=O)OP(O)(O)=O KCRZDTROFIOPBP-UHFFFAOYSA-N 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 239000001259 polydextrose Substances 0.000 description 1
• 235000013856 polydextrose Nutrition 0.000 description 1
• 229940035035 polydextrose Drugs 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 230000022558 protein metabolic process Effects 0.000 description 1
• 238000000575 proteomic method Methods 0.000 description 1
• 101150091633 psuG gene Proteins 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• 244000000070 pulmonary pathogen Species 0.000 description 1
• 235000008151 pyridoxamine Nutrition 0.000 description 1
• 239000011699 pyridoxamine Substances 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 238000003753 real-time PCR Methods 0.000 description 1
• 101150066870 recG gene Proteins 0.000 description 1
• 235000020201 recombined milk Nutrition 0.000 description 1
• 229940100618 rectal suppository Drugs 0.000 description 1
• 239000006215 rectal suppository Substances 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 101150044854 repA gene Proteins 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 235000021254 resistant starch Nutrition 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 239000012146 running buffer Substances 0.000 description 1
• 238000011076 safety test Methods 0.000 description 1
• 238000006748 scratching Methods 0.000 description 1
• 230000002393 scratching effect Effects 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 235000020254 sheep milk Nutrition 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 239000002356 single layer Substances 0.000 description 1
• 235000020183 skimmed milk Nutrition 0.000 description 1
• 210000003625 skull Anatomy 0.000 description 1
• 239000000344 soap Substances 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
• 235000015921 sodium selenite Nutrition 0.000 description 1
• 239000011781 sodium selenite Substances 0.000 description 1
• 229960001471 sodium selenite Drugs 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 238000013112 stability test Methods 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 101150038671 strat gene Proteins 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 150000005846 sugar alcohols Chemical class 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 230000009747 swallowing Effects 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 239000010409 thin film Substances 0.000 description 1
• 210000000779 thoracic wall Anatomy 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 239000003440 toxic substance Substances 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• 201000008297 typhoid fever Diseases 0.000 description 1
• 229910021642 ultra pure water Inorganic materials 0.000 description 1
• 239000012498 ultrapure water Substances 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 235000019154 vitamin C Nutrition 0.000 description 1
• 239000011718 vitamin C Substances 0.000 description 1
• 230000002747 voluntary effect Effects 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 208000016261 weight loss Diseases 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 235000008939 whole milk Nutrition 0.000 description 1
• BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
• 229960001600 xylazine Drugs 0.000 description 1
• 108091016328 xylose binding proteins Proteins 0.000 description 1
• 235000013618 yogurt Nutrition 0.000 description 1